Table 4.

Intravenous Iron Therapy for RLS-A-CKS.

TREATMENT	NUMBER OF PATIENTS	STUDY DESIGN	DOSE, DURATION	RESULTS	SIDE EFFECTS
Intravenous (IV) iron dextran [58]	25 Iron dextran: 11 Placebo: 14	Double blind- placebo controlled	Iron dextran: 1000 mg Study duration: 4 weeks. IRLS intensity scores were assessed weekly	At weeks 1 and 2 post-injection, patients in the Iron treated group showed significant reduction of IRLS scores (P = 0.01 and P = 0.03). At week 4, though still lower than placebo, the difference was not statistically significant	No difference in adverse effects between the two groups
Intravenous iron sucrose [59]	30 IV Iron Sucrose: 16 Placebo: 16	Randomized, placebo-controlled	Iron sucrose: 100 mg, three times/week for a total of 1000 mg. Study duration: 3 weeks	After two weeks, IRLS scores (compared to baseline) were significantly reduced compared to placebo group (P = 0.000). Improvement of IRLS score in the iron group continued for 4–24 weeks.	No adverse effects
Intravenous iron sucrose [60]	18 Iron sucrose:11 Placebo:7	Double blind- placebo controlled	500 mg of Iron sucrose was administered IV in two successive days for a total of 1000 mg Study duration: 4 weeks Primary outcome for RLS symptom improvement was global rating scale (GRS)	The trial was aborted half- way into the study since despite some improvement in GRS (at two weeks), authors predicted lack of robust response at the end of the study	Edema in either hands or feet (36%). Nausea or vomiting (36%). Hypotension (18%). dizziness (18%). abdominal pain (9%). All noted during infusion only.

GRS: Global rating Scale.